Full Text View
Tabular View
No Study Results Posted
Related Studies
Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction
This study has been completed.
First Received: September 2, 2005   Last Updated: January 12, 2007   History of Changes
Sponsor: Pfizer
Information provided by: Pfizer
ClinicalTrials.gov Identifier: NCT00147654
  Purpose

The primary objective of the trial is to evaluate the effect of tolterodine ER plus tamsulosin versus placebo on patient perception of overall treatment benefit in men who have frequency and urgency, with or without urinary urge incontinence (UUI), with or without bladder outlet obstruction (BOO).


Condition Intervention Phase
Urinary Incontinence
 Drug: Tolterodine ER 4 mg QD
Drug: Tamsulosin 0.4 mg QD
 Phase IV

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety Study
Official Title: A Randomized, Double Blind, Placebo Controlled, Four Arm (Placebo, Tolterodine ER, Tamsulosin, and Tolterodine ER Plus Tamsulosin) Study To Evaluate The Clinical Efficacy And Safety Of Tolterodine ER 4 mg In Men Who Have Frequency and Urgency, With Or Without Urinary Urge Incontinence, With Or Without Bladder Outlet Obstruction

Resource links provided by NLM:

MedlinePlus related topics: Urinary Incontinence Urine and Urination
Drug Information available for: Tamsulosin Tamsulosin hydrochloride Tolterodine Tolterodine tartrate
U.S. FDA Resources

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Patient Perception of Treatment Benefit at Week 12:
  • Treatment benefit, treatment satisfaction, and willingness to continue treatment questions at week 12

Secondary Outcome Measures:
  • Micturition Diary- •Change in number of urge incontinence episodes per 24 hours at week 1, week 6 and 12
  • relative to baseline
  • Change in number of urge episodes per 24 hours at week 1, week 6 and 12 relative to
  • baseline
  • Change in number of micturitions per 24 hours at week 1, week 6 and 12 relative to
  • Change in number of daytime micturitions per 24 hours at week 1, week 6 and 12 relative to baseline
  • Change in number of nighttime micturitions per 24 hours at week 1, week 6 and 12 relative to baseline
  • Change in the average severity of the Urinary Sensation Scale at week 1, week 6, and week 12 relative to baseline
  • Change in number of OAB micturition episodes per 24 hours (OAB micturition is defined as
  • micturition episodes associated with Urinary Sensation Scale score  3) at week 1, week 6 and week 12 relative to baseline
  • Change in number of daytime OAB micturition episodes per 24 hours
  • (OAB micturition is defined as micturition episodes associated with Urinary Sensation Scale score  3) at week 1, week 6 and week 12 relative to baseline
  • Change in number of nighttime OAB micturition episodes per 24 hours
  • Change in number of severe OAB micturition episodes per 24 hours
  • (severe OAB micturition is defined as micturition episodes associated with Urinary Sensation Scale score  4) at week 1, week 6 and week 12 relative to baseline
  • Change in number of daytime severe OAB micturition episodes per 24 hours
  • Change in number of nighttime severe OAB micturition episodes per 24 hours
  • International Prostate Symptom Score (I-PSS):
  • Change in I-PSS total score at weeks 1, 6 and 12 relative to baseline
  • Change in I-PSS individual item scores (Q1, Q2, Q3, Q4, Q5, Q6, and Q7) at weeks 1, 6 and 12 relative to baseline
  • Change in I-PSS irritative domain (Sum of Q2, Q4, and Q7) at weeks 1, 6 and 12 relative to baseline
  • Change in I-PSS obstructive domain (Sum of Q1, Q3, Q5, and Q6) at weeks 1, 6 and 12 relative to baseline
  • Change in I-PSS index score (Sum Q1 to Q7) at weeks 1, 6 and 12 relative to baseline
  • Change in I-PSS QoL score (Q8) at weeks 1, 6 and 12 relative to baseline
  • Patient perception of urgency:
  • Change in the Perception of Urgency Scale (3 point scale) at week 1, week 6 and week 12 relative to baseline
  • Change in Patient’s Perception of Bladder Condition at week 1, week 6 and week 12 relative to baseline
  • Patient Perception of Treatment benefit at week 1 and week 6
  • Treatment benefit and treatment satisfaction questions will be completed at week 1
  • and week 6
  • Change in International Continence Society Male (ICSmaleLF) Questionnaire (long form modified) individual item scores at Week 1, Week 6 and Week 12 relative to baseline
  • Change in the total score of Overactive Bladder Questionnaire (OABq) and change in total scores for each domain of OABq at week 6 and week 12 relative to baseline
  • Change in the total score of International Index of Erectile Function (IIEF) and change in total scores for each domain of IIEF Questionnaire at week 6 and week 12 relative to baseline

Estimated Enrollment: 830
Study Start Date: November 2004
  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male 40 years of age
  • Clinical signs and symptoms of frequency and urgency, with or without UUI, with or without BOO, for at least three months
  • Mean urinary frequency of 8 micturitions/24h verified by the Screening micturition diary

Exclusion Criteria:

  • Post-void residual urine volume (PVR) of > 200 ml as measured by an ultrasound
  • Maximum urinary flow rate (Qmax) of < 5 ml/second as measured by a flowmeter; a voided volume of 75 ml is required in order to accurately record the Qmax
  • Prescribed and administered an antimuscarinic or antispasmodic within 1 month
  • Prescribed and administered an a-1-adrenergic antagonist within 2 weeks
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00147654

  Hide Study Locations
Locations
United States, Alabama
Pfizer Investigational Site
Homewood, Alabama, United States
Pfizer Investigational Site
Birmingham, Alabama, United States
United States, Arizona
Pfizer Investigational Site
Tucson, Arizona, United States
United States, California
Pfizer Investigational Site
Fresno, California, United States
Pfizer Investigational Site
Anaheim, California, United States
Pfizer Investigational Site
Santa Monica, California, United States
Pfizer Investigational Site
Long Beach, California, United States
Pfizer Investigational Site
La Mesa, California, United States
Pfizer Investigational Site
Culver City, California, United States
Pfizer Investigational Site
Murrieta, California, United States
Pfizer Investigational Site
San Bernardino, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Poway, California, United States
United States, Colorado
Pfizer Investigational Site
Aurora, Colorado, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Boulder, Colorado, United States
United States, Connecticut
Pfizer Investigational Site
Waterbury, Connecticut, United States
Pfizer Investigational Site
New Britain, Connecticut, United States
United States, Florida
Pfizer Investigational Site
Ocala, Florida, United States
Pfizer Investigational Site
Melbourne, Florida, United States
Pfizer Investigational Site
Tallahassee, Florida, United States
Pfizer Investigational Site
Wellington, Florida, United States
Pfizer Investigational Site
Pembroke Pines, Florida, United States
United States, Georgia
Pfizer Investigational Site
Roswell, Georgia, United States
Pfizer Investigational Site
Atlanta, Georgia, United States
Pfizer Investigational Site
Columbus, Georgia, United States
United States, Illinois
Pfizer Investigational Site
Melrose Park, Illinois, United States
United States, Indiana
Pfizer Investigational Site
Jeffersonville, Indiana, United States
Pfizer Investigational Site
Evansville, Indiana, United States
United States, Iowa
Pfizer Investigational Site
Iowa City, Iowa, United States
United States, Kansas
Pfizer Investigational Site
Overland Park, Kansas, United States
United States, Louisiana
Pfizer Investigational Site
Shreveport, Louisiana, United States
United States, Massachusetts
Pfizer Investigational Site
Brighton, Massachusetts, United States
Pfizer Investigational Site
Watertown, Massachusetts, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
United States, Missouri
Pfizer Investigational Site
O'Fallon, Missouri, United States
Pfizer Investigational Site
St. Louis, Missouri, United States
Pfizer Investigational Site
Columbia, Missouri, United States
Pfizer Investigational Site
St. Louis, Missouri, United States
United States, Montana
Pfizer Investigational Site
Missoula, Montana, United States
United States, Nevada
Pfizer Investigational Site
Las Vegas, Nevada, United States
Pfizer Investigational Site
Henderson, Nevada, United States
United States, New Jersey
Pfizer Investigational Site
Marlton, New Jersey, United States
Pfizer Investigational Site
Voorhees, New Jersey, United States
Pfizer Investigational Site
Woodbury, New Jersey, United States
Pfizer Investigational Site
Lawrenceville, New Jersey, United States
Pfizer Investigational Site
Cherry Hill, New Jersey, United States
Pfizer Investigational Site
Edison, New Jersey, United States
Pfizer Investigational Site
Hamilton, New Jersey, United States
Pfizer Investigational Site
Mt. Laurel, New Jersey, United States
Pfizer Investigational Site
Westhampton, New Jersey, United States
Pfizer Investigational Site
Sewell, New Jersey, United States
United States, New Mexico
Pfizer Investigational Site
ALbuquerque, New Mexico, United States
United States, New York
Pfizer Investigational Site
Garden City, New York, United States
Pfizer Investigational Site
Manhasset, New York, United States
Pfizer Investigational Site
Bayshore, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Syracuse, New York, United States
Pfizer Investigational Site
Orchard Park, New York, United States
Pfizer Investigational Site
Poughkeepsie, New York, United States
Pfizer Investigational Site
Carmel, New York, United States
Pfizer Investigational Site
Cortlandt Manor, New York, United States
Pfizer Investigational Site
Albany, New York, United States
Pfizer Investigational Site
Staten Island, New York, United States
United States, Ohio
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Columbus, Ohio, United States
United States, Oklahoma
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States
United States, Oregon
Pfizer Investigational Site
Portland, Oregon, United States
United States, Pennsylvania
Pfizer Investigational Site
Bala Cynwyd, Pennsylvania, United States
Pfizer Investigational Site
State College, Pennsylvania, United States
Pfizer Investigational Site
Allentown, Pennsylvania, United States
Pfizer Investigational Site
Wynnewood, Pennsylvania, United States
Pfizer Investigational Site
Bryn Mawr, Pennsylvania, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
United States, Rhode Island
Pfizer Investigational Site
Providence, Rhode Island, United States
United States, South Carolina
Pfizer Investigational Site
Charleston, South Carolina, United States
Pfizer Investigational Site
Greer, South Carolina, United States
Pfizer Investigational Site
Prosperity, South Carolina, United States
Pfizer Investigational Site
Saluda, South Carolina, United States
Pfizer Investigational Site
Greenwood, South Carolina, United States
United States, Tennessee
Pfizer Investigational Site
Germantown, Tennessee, United States
Pfizer Investigational Site
Milan, Tennessee, United States
United States, Texas
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Arlington, Texas, United States
Pfizer Investigational Site
Austin, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
United States, Utah
Pfizer Investigational Site
Provo, Utah, United States
United States, Virginia
Pfizer Investigational Site
Charlotesville, Virginia, United States
Pfizer Investigational Site
Virginia Beach, Virginia, United States
Pfizer Investigational Site
Fairfax, Virginia, United States
Pfizer Investigational Site
Arlington, Virginia, United States
Pfizer Investigational Site
Alexandria, Virginia, United States
United States, Washington
Pfizer Investigational Site
Tacoma, Washington, United States
Pfizer Investigational Site
Spokane, Washington, United States
United States, Wyoming
Pfizer Investigational Site
Cheyenne, Wyoming, United States
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
To obtain contact information for a study center near you, click here.  This link exits the ClinicalTrials.gov site

No publications provided by Pfizer

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):
Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006 Nov 15;296(19):2319-28. Erratum in: JAMA. 2007 Mar 21:297(11):1195.

Study ID Numbers: A6121120
Study First Received: September 2, 2005
Last Updated: January 12, 2007
ClinicalTrials.gov Identifier: NCT00147654     History of Changes
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Neurotransmitter Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Urination Disorders
Antineoplastic Agents
Physiological Effects of Drugs
Urinary Bladder Diseases
Urethral Obstruction
Adrenergic alpha-Antagonists
Cholinergic Agents
Pharmacologic Actions
 Muscarinic Antagonists
Urological Manifestations
Signs and Symptoms
Urologic Diseases
Therapeutic Uses
Tamsulosin
Urethral Diseases
Adrenergic Antagonists
Urinary Bladder Neck Obstruction
Urinary Incontinence
Tolterodine

ClinicalTrials.gov processed this record on November 27, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services